A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies

Protocol: 
AAAP2403
Phase: 
I

A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death – 1 (PD-1), as single therapy and in combination with other anti-cancer therapies, in patients with advanced malignancies

Are you Eligible? (Inclusion Criteria)

1. Pathologically confirmed solid tumor with no alternative standard treatment
options
2. No prior therapy with an agent targeting PD1 or PD-L1
3. Select study cohorts will require the presence of one tumor lesion that can be
safely treated with radiotherapy
4. Adequate bone marrow and organ function is required

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States